Restoring effects of oxytocin on the attentional preference for faces in autism by Kanat, Manuela et al.
OPEN
ORIGINAL ARTICLE
Restoring effects of oxytocin on the attentional preference
for faces in autism
M Kanat1,2, I Spenthof1,3, A Riedel4, LT van Elst2,4, M Heinrichs1,2 and G Domes1,2,3
Reduced attentional preference for faces and symptoms of social anxiety are common in autism spectrum disorders (ASDs). The
neuropeptide oxytocin triggers anxiolytic functions and enhances eye gaze, facial emotion recognition and neural correlates of face
processing in ASD. Here we investigated whether a single dose of oxytocin increases attention to faces in ASD. As a secondary
question, we explored the inﬂuence of social anxiety on these effects. We tested for oxytocin’s effects on attention to neutral faces
as compared to houses in a sample of 29 autistic individuals and 30 control participants using a dot-probe paradigm with two
different presentation times (100 or 500 ms). A single dose of 24 IU oxytocin was administered in a randomized, double-blind
placebo-controlled, cross-over design. Under placebo, ASD individuals paid less attention to faces presented for 500 ms than did
controls. Oxytocin administration increased the allocation of attention toward faces in ASD to a level observed in controls.
Secondary analyses revealed that these oxytocin effects primarily occurred in ASD individuals with high levels of social anxiety who
were characterized by attentional avoidance of faces under placebo. Our results conﬁrm a positive inﬂuence of intranasal oxytocin
on social attention processes in ASD. Further, they suggest that oxytocin may in particular restore the attentional preference for
facial information in ASD individuals with high social anxiety. We conclude that oxytocin’s anxiolytic properties may partially
account for its positive effects on socio-cognitive functioning in ASD, such as enhanced eye gaze and facial emotion recognition.
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INTRODUCTION
Autism spectrum disorders (ASDs) are associated with difﬁculties
in understanding facial cues that potentially arise from reduced
attraction by social information in association with a disturbed
development of neural face processing networks during early
infancy.1,2 For example, autistic children display less attentional
orienting but enhanced attentional disengagement from facial
cues.3,4 Within the past few years, the neuropeptide oxytocin has
been shown to enhance socio-cognitive functions that are
frequently impaired in ASDs. For example, intranasal administra-
tion of oxytocin improved performance in facial emotion recogni-
tion tasks,5–7 increased social trust8,9 and selectively strengthened
emotion perceptions for face cues but not for nonsocial
information.10 These effects may partially rely on oxytocin’s
modulatory inﬂuences on social attention processes, such as
enhanced eye gaze11–13 or valence-dependent orienting of
attention toward emotional expressions.12,14,15
Notably, oxytocin effects on attention16 and empathic
accuracy17 were shown to be particularly pronounced in healthy
individuals with higher autistic traits. In persons diagnosed with
ASD, intranasally administered oxytocin seems to facilitate social
interactions and feelings of trust,18 promote mentalizing abilities
based on facial features19–21 and to increase eye gaze.11,18 In addi-
tion, imaging studies demonstrated enhancing effects of oxytocin
on functioning of the social brain in ASD, as observed during the
processing of face cues20,22,23 and social judgments,24,25 including
the inference of facial emotions.26 However, it remains unclear
whether oxytocin initially increases social orienting in ASD and
thereby potentially corrects for a characteristic impairment that is
already observed in autistic children aged 2–5 years.3,4 Beyond
this background, the primary hypothesis of our study was that
oxytocin enhances attention for social as compared to nonsocial
information in ASD. To test these hypotheses, we measured the
effects of a single dose of intranasal oxytocin on attention to face
and house pictures in the well-established dot-probe task.27
Attention for social cues is known to be modulated by anxiety
levels. For example, social anxiety has been associated with an
attentional bias for negative facial expressions28 and attentional
avoidance of the eye region, particularly for angry faces.29
Symptoms of social anxiety are common in individuals with
high-functioning autism and Asperger syndrome, and seem to
worsen with age.30,31 Notably, individual levels of social anxiety
predict attentional avoidance of the eye region32 and intensify
impairments in gazing toward a virtual audience in ASD33
suggesting that social anxiety may increase social attention
deﬁcits as commonly observed in ASD. In contrast, the neuropep-
tide oxytocin is assumed to reduce symptoms of social anxiety by
lowering the responsiveness towards social evaluations34 and
threat-related facial information.35–37 Imaging studies suggest that
oxytocin may attenuate arousal by socially threatening informa-
tion by modulating activity in the amygdala and associated brain
areas.35,36,38,39 As a secondary question, we therefore explored
whether oxytocin’s effects on social attention in autistic indivi-
duals might be inﬂuenced by social anxiety as measured by a trait
questionnaire.40
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MATERIALS AND METHODS
Subjects
A total number of 29 male autistic individuals with Asperger syndrome
(ASD group; mean age± s.d.: 38.2 ± 10.6) and 31 neurotypical control
subjects (NT group; mean age± s.d.: 31.7 ± 12.3) participated in the study.
The sample size was based on previous studies investigating effects of
oxytocin on attention processes in ASD.11,18 Women were excluded from
participation due to the greater prevalence of ASD in males and to avoid
confounding effects of hormonal changes across the menstrual cycle with
oxytocin administration. Due to his extreme value in our social anxiety
measure, one subject from the neurotypical control sample was excluded
from all analyses. Demographic and clinical characteristics of the ﬁnal
sample are described in Table 1. The ASD group scored higher on
measures of autism and social anxiety. Both groups were similar in their
verbal intelligence and years of education, but the autistic individuals were
signiﬁcantly older than the controls.
Individuals with ASD were mainly out-patients recruited via the Clinic for
Psychiatry and Psychotherapy of the University Hospital Freiburg where
they had been diagnosed by experienced clinicians. Diagnosis was
subsequently validated with Module 4 of the Autism Diagnostic
Observation Schedule41 by trained members of our research team. This
procedure led us to exclude two potential participants, one of whom did
not fulﬁll ASD cutoff criteria, whereas we suspected the other of having
cognitive and verbal impairments, leading to the diagnosis of an autistic
disorder rather than Asperger syndrome. In addition, comorbidities were
assessed by means of self-report. In total, 20 out of 29 participants with
ASD (69.0%) reported present or past psychiatric comorbidities, mostly
depressive (n= 18), attention-deﬁcit/hyperactivity (n=7), or anxiety
disorders (n= 6; for example, social phobia, panic disorder). The majority
of ASD individuals (n=18; 62.1%) took psychoactive drugs regularly,
including antidepressants and neuroleptics. Neurotypical control subjects
were recruited via institutional bulletin boards. They had no physical or
psychiatric illness and were not taking any medications as revealed during
a thorough interviewing process including the German version of the
Structured Clinical Interview for DSM-IV Disorders.42 Subjects gave their
written informed consent prior to participation and were paid at the end of
the last testing session. The study protocol concurred with the Declaration
of Helsinki, was approved by the ethics committee of the University
Hospital Freiburg and registered in the European Union Clinical Trials
Register (EudraCT number 2010-022511-18; URL: https://www.clinicaltrials
register.eu; registration date: 17 August 2010).
Participants completed a set of standardized questionnaires on
demographic, clinical and personality variables. These comprised the
German translations of the Social Interaction Anxiety Scale that assesses
anxiety symptoms in social interactions,40 the Autism-Spectrum Quotient43
and the Wortschatztest44 as an estimate of verbal intelligence. In addition,
participants completed a three-scale state questionnaire immediately
before nasal spray administration and prior to the beginning of the
experimental task in which they rated mood, wakefulness and arousal.45
Experimental procedures
Participants came for two testing sessions 14 days apart, ﬁlling out a
questionnaire addressing current medical and psychological conditions at
each session. Thereafter, they self-administered three puffs of a nasal spray
containing either oxytocin (Syntocinon Spray, Novartis, Basel, Switzerland)
or a placebo (containing all ingredients, except the neuropeptide) in each
nostril. For the oxytocin spray, this procedure added up to a total dosage
of 24 IU. Half of the participants received oxytocin at the ﬁrst testing
session and placebo on the second session in randomized, double-blind
fashion. Randomization was done in blocks for 10 participants each by the
University Hospital of Heidelberg’s pharmacy, which provided the nasal
sprays and unblinded the research team on each participant’s drug-
administration sequence after the completion of data collection. Approxi-
mately 45 min following substance administration, participants were
seated in front of a computer screen, and completed a dot-probe task
that assesses the attentional preference for a target stimulus as compared
to a simultaneously presented distractor stimulus based on reaction times
to a subsequent probe.27
In the dot-probe task, a set of 12 faces selected from the Karolinska
directed emotional faces database46 served as social target stimuli. These
face pictures were compared to 12 house pictures already used in a
another study22 that served as nonsocial distractor stimuli. All pictures
were converted to gray-scale and had a ﬁnal size of 200x200 pixels. They
were presented against a gray background and displayed on a 22" TFT
screen (40.8 × 30.6 cm; 1680x1050 pixels) at a constant viewing distance of
65 cm assured using a chin rest. Trial structure and experimental
conditions are depicted in Figure 1. Each trial started with a black ﬁxation
cross in the center of the screen for 1500–2000 ms. Then, two pictures
were presented simultaneously in the left and right hemisphere at a
horizontal distance of 800 pixels and lasting either 100 or 500 ms.
Immediately after presentation of the two pictures, the probe (a small gray
square, 10x10 pixels) appeared in one of their positions. During the target
trials, pictures of a house and a face were simultaneously presented and
the probe was cued by a face (congruent) or a house (incongruent) in half
of the trials. During the ﬁller trials, either two houses or two faces were
displayed. Subjects indicated the location of the probe by pressing one of
two buttons as quickly and accurately as possible. The task comprised a
total of 96 trials, half of which represented target trials or ﬁller trials. We
used Presentation (www.neurobs.com) to control picture presentation and
record the number of correct responses and reaction times to the dot
probes.
Statistical analysis
First, we excluded all trials revealing erroneous responses or implausible
reaction times (o200 ms or 42500 ms) from further analysis. This
accounted for 118 trials (1.0%) of the 11 328 trials presented to the 59
participants. Reaction time (RT) data from valid trials was entered into a
repeated measures analysis of variance (ANOVA) with the factors group
(ASD, NT), drug condition (placebo, oxytocin), prime duration (100, 500 ms)
and probe location (congruent, incongruent). Attentional bias scores were
calculated by subtracting the median RT in congruent trials from that in
incongruent trials, with positive values reﬂecting increased attention for the
target stimulus (that is, a face). In addition, we accounted for two distinct
attention components integrated within the attentional bias, namely the
initial allocation of attention to the salient prime (vigilance), and the ability
to disengage attention from the prime (adherence), that is, adherence.47
The initial allocation of attention to the target stimulus is indicated by
faster responses in congruent target trials than in ﬁller trials (ΔRTallocation =
RTﬁller− RTcongruent). In contrast, adherence to the target stimulus is
revealed by slower responses in incongruent target trials than in ﬁller
trials (ΔRTadherence = RTincongruent− RTﬁller). While we had also included ﬁller
trials with faces to prevent faces from having an attentional advantage
solely because of a face event’s infrequency, only ﬁller trials entailing the
simultaneous presentation of two houses were used to calculate allocation
and adherence scores.
Table 1. Demographic and clinical characteristics of the study groups
ASD (n= 29) NT (n= 30) Statistical test
Mean (s.d.) Mean (s.d.)
Age (years) 38.2 (10.6) 32.1 (12.3) T57= 2.04, P= 0.046
Years in school 13.4 (1.7) 12.9 (0.9) T40.49= 1.27, P= 0.212
Verbal intelligence (WST) 34.3 (5.0) 34.2 (3.0) T56= 0.11, P= 0.911
Autistic symptoms (AQ) 37.8 (8.1) 18.9 (6.8) T56= 9.68, Po0.001
Social anxiety (SIAS) 45.4 (14.4) 22.0 (11.1) T56= 6.91, Po0.001
Abbreviations: AQ, Autism Spectrum Quotient; ASD, autism spectrum disorder; NT, neurotypical; SIAS, Social Interaction Anxiety Scale; WST, Wortschatztest.
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All three attention scores were analyzed within separate ANOVAs with
the factors group (ASD, NT), drug condition (placebo, oxytocin) and prime
duration (100, 500 ms). To explore the inﬂuence of social anxiety on
attention processes in ASD, we calculated correlations between attention
measures and individual anxiety levels. Due to a signiﬁcant correlation
within the ASD group under placebo conditions, we subsequently split the
ASD group into a low and a highly anxious subsample based on the group
median. For the ASD group only, we then calculated a three-way ANOVA
with the between-subjects factor social anxiety (low, high), drug condition
(placebo, oxytocin) and prime duration (100, 500 ms). All statistical
analyses were run in IBM SPSS Statistics 21 (IBM, Armonk, NY, USA) with
a statistical signiﬁcance threshold of Po0.05 (two-sided testing). In case
the assumption of sphericity was violated, we applied a Greenhouse–
Geisser correction.
RESULTS
Raw reaction time data
Our initial analysis of raw RT data revealed the probe location’s
signiﬁcant main effect, with longer response latencies for
incongruent probe locations indicating increased attentional
capture by faces as compared to houses (F1,57 = 26.90,
Po0.001). While ASD individuals were generally slower in
responding to the probe (F1,57 = 21.55, Po0.001), there was no
signiﬁcant interaction between probe location and group (F1,57
= 0.35, P= 0.558) nor between probe location and drug condition
(F1,57 = 0.543, P= 0.464). Hence, the attentional preference for face
stimuli was similar in both groups and independent of oxytocin
administration. In contrast, we observed a signiﬁcant three-way
interaction of duration, drug and group (F1,57 = 4.530, P= 0.038):
oxytocin administration tended to reduce response latencies in
the NT group for the short stimulus condition (100 ms), and in the
ASD group for the long stimulus condition (500 ms). However,
within subsequent pairwise analyses, none of these effects
reached signiﬁcance (see Table 2 for raw reaction time data).
Attentional bias
We next analyzed group differences for the attentional bias (that
is, the difference between RTs for incongruent versus congruent
probe locations) and its modulations by prime duration and
Figure 1. Trial structure and experimental conditions of the house–face dot-probe paradigm.
Table 2. Average raw reaction times (in ms) for the different conditions in the house–face dot-probe paradigm
ASD (n= 29) NT (n=30)
Placebo Oxytocin Placebo Oxytocin
Median (s.d.) Median (s.d.) Median (s.d.) Median (s.d.)
100 ms
Trials congruent 463.1 (57.4) 462.1 (50.6) 407.8 (41.1) 397.8 (46.3)
Trials incongruent 472.9 (71.2) 467.9 (58.1) 415.2 (41.2) 408.3 (39.9)
Filler house 471.4 (53.2) 474.4 (52.2) 413.9 (37.8) 414.7 (44.5)
500 ms
Trials congruent 462.3 (68.6) 444.3 (55.8) 399.2 (38.7) 398.5 (44.3)
Trials incongruent 467.8 (65.5) 461.6 (67.6) 414.4 (47.7) 413.6 (46.1)
Filler house 462.3 (64.3) 459.7 (60.3) 418.5 (38.4) 412.6 (43.1)
Abbreviations: ASD, autism spectrum disorder; NT, neurotypical.
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oxytocin administration. The corresponding three-way ANOVA
yielded no signiﬁcant results, neither for the main effects nor any
of the interactions. Thus, the attentional preference for face stimuli
was similar in ASD individuals and NT controls, and not modulated
by prime duration or oxytocin administration.
Allocation versus adherence
Within separate ANOVAs, we tested for effects on vigilance, that is,
the initial allocation of attention toward faces, and adherence, that
is, difﬁculty disengaging attention from faces.
We observed no signiﬁcant group differences, effects of prime
duration or interactions between the two under placebo
conditions in the adherence scores (all P40.05). A subsequent
three-way ANOVA with the additional factor drug condition
revealed no signiﬁcant effects of oxytocin administration on
adherence (all P40.05), indicating that the difﬁculty in disenga-
ging attention from faces was not inﬂuenced by group, prime
duration or drug condition.
Regarding the allocation scores, a two-way ANOVA with the
factors group and prime duration revealed a signiﬁcant interaction
between both factors under placebo conditions (F1,57 = 6.10,
P= 0.017): individuals with ASD and the controls both allocated
attention similarly to faces in the brief stimulus condition (t57
= 0.38, P= 0.704) whereas the ASD group exhibited a lower initial
allocation of attention to face stimuli in the long stimulus
condition (t57 =− 2.58, P= 0.012). In a subsequent three-way
ANOVA with the additional factor drug condition, we noted a
main effect of drug condition on the initial allocation of attention
to faces: oxytocin administration generally increased the alloca-
tion of attention to faces as compared to houses (F1,57 = 4.27,
P= 0.043). This effect was further modulated by group and prime
duration, as indicated by a signiﬁcant three-way interaction
(F1,57 = 4.10, P= 0.048) (Figure 2). Pairwise comparisons showed
that oxytocin tended to enhance attention to faces in the NT
group for the short stimulus condition (t29 =− 1.97, P= 0.059). In
contrast, oxytocin signiﬁcantly enhanced attention to faces as
compared to houses in the ASD group for presentations of 500 ms
(t28 =− 2.63, P= 0.014), thereby eliminating the impaired social
attention observed under placebo conditions.
The inﬂuence of social anxiety on the allocation of attention to
faces
Within secondary analyses, we next explored whether social
anxiety levels inﬂuenced the initial allocation of attention to faces.
In the ASD group, allocation of attention to faces showed a
signiﬁcant negative correlation with individual levels of social
anxiety under placebo conditions, indicating reduced attention to
faces in highly anxious persons (ASDPlacebo: r=− 0.56, P= 0.002)
(Figure 3). We observed a similar correlation within the NT group,
but it failed to reach statistical signiﬁcance (NTPlacebo: r=− 0.30,
P= 0.119). Following oxytocin administration, the negative asso-
ciation between social anxiety and attention to faces was reduced
in the ASD group (ASDOxytocin: r=− 0.20, P= 0.289) and vanished in
the NT group (NTOxytocin: r = 0.05, P= 0.785). The difference
between the two correlations under placebo and oxytocin
conditions approached signiﬁcance in both groups (ASD: z=
− 1.50, P= 0.07; NT: z=− 1.61, P= 0.05).
We subsequently included social anxiety as a covariate in our
three-way analysis of variance on allocation scores (factors group,
prime duration and drug condition). This analysis yielded a
signiﬁcant effect of anxiety on allocation scores (F1,55 = 8.46,
P= 0.005) as well as a signiﬁcant interaction between anxiety and
oxytocin administration (F1,55 = 4.68, P= 0.035). Of note, neither
the above-reported main effect of oxytocin administration nor the
interaction between drug condition, stimulus duration and group
continued to be signiﬁcant (all P40.05). Separate analyses in both
groups showed a signiﬁcant effect of social anxiety in the ASD
group (F1,27 = 10.51, P= 0.003) but no effects of or interactions
with oxytocin administration (all P40.05). The NT group exhibited
no signiﬁcant effects (all P40.05).
To elucidate the modulating role of social anxiety in the ASD
group, we subsequently split the sample by median, thereby
differentiating between individuals with high and low levels of
social anxiety. In a three-way ANOVA with the factors drug
condition, prime duration and the group factor social anxiety, a
trend for a three-way interaction emerged (F1,27 = 3.58, P= 0.069)
(Figure 4). Pairwise comparisons of this interaction proved that
oxytocin selectively inﬂuenced the allocation of attention to faces
in highly anxious ASD subjects in the long stimulus condition: A
single dose of oxytocin induced attentional orienting toward face
stimuli and thereby reversed attentional avoidance as suggested
Figure 2. Effects of intranasal oxytocin on allocation of attention to faces versus houses presented with (a) short duration (100 ms) or (b) long
duration (500 ms). Error bars represent the s.e.m. *t28=− 2.63, P= 0.014. ASD, autism spectrum disorder; NT, neurotypical.
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by negative allocation scores under placebo conditions (t14 =
− 2.92, P= 0.011). In contrast, no other comparison attained
signiﬁcance (all P40.05).
DISCUSSION
Our study delivers initial evidence that the neuropeptide oxytocin
may enhance visual attention toward face cues in ASD to a level
observed in neurotypical controls. These positive effects of
oxytocin on social attention seem to primarily occur in ASD
individuals characterized by high levels of social anxiety and
concomitant attentional avoidance of faces.
The absence of an overall attentional bias toward target stimuli
(that is, faces) in our study may be due to the fact that attentional
bias integrates two distinct attention components, namely the
initial allocation of attention and the adherence of attention
to a target stimulus, which might negate each other.47 By
differentiating between these components, we found that
individuals with ASD were impaired in vigilance, that is, the initial
allocation of attention toward faces, but demonstrated normal
disengagement from facial information. Our results concur with
eye-tracking studies reporting a slower initial orientation toward
social information in autistic samples as reﬂected by longer
latency to ﬁrst ﬁxate social cues.48,49 While we did not assess eye
movements in our study, we observed impairments in the initial
allocation of attention to social cues in ASD for presentations
lasting 500 ms, that is, at a stage of stimulus processing that likely
matched early gazes to one of the two pictures. In contrast, we
observed no attentional differences between ASD and neuroty-
pical individuals in conjunction with 100 ms presentation times,
which refer to covert attentional processes. Alterations in social
attention in ASD may therefore relate to an early stage of
attentional processing, namely the ﬁrst overt attention shift
following conscious stimulus perception.50
Figure 4. Inﬂuence of high and low social anxiety on oxytocin’s effect on the ASD group’s allocation of attention toward faces versus houses
presented with (a) short duration (100 ms) or (b) long duration (500 ms). Error bars represent the s.e.m. *t14=− 2.92, P= 0.011. ASD, autism
spectrum disorder; SIAS, Social Interaction Anxiety Scale.
Figure 3. Association between the allocation of attention to faces in the dot-probe task and social anxiety in both groups and its modulation
by oxytocin administration. (a) In the neurotypical control group, social anxiety showed a weak negative association with attention to faces
under placebo (r=− 0.30, P= 0.119), which vanished following oxytocin administration (r = 0.05, P= 0.785). (b) In the autistic group, social
anxiety signiﬁcantly predicted attentional avoidance of faces under placebo (r=− 0.56, Po0.05), whereas this association was no longer
signiﬁcant under oxytocin (r=− 0.20, P= 0.289). ASD, autism spectrum disorder; NT, neurotypical; SIAS, Social Interaction Anxiety Scale.
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It has been proposed that decreased attention to faces in ASD
may either stem from insufﬁcient emotional salience and
motivational indifference toward these cues, or from avoidance
behavior as a strategy to regulate heightened arousal.51 In our
study, exploratory analyses revealed that the initial allocation of
attention to faces was much weaker in ASD individuals with high
than with low levels of social anxiety, potentially indicating
arousal-related attentional avoidance rather than reduced stimu-
lus salience in this subgroup. Notably, we also observed a negative
association between social anxiety and the initial allocation of
attention toward faces in the neurotypical control sample that did
not reach statistical signiﬁcance, which may partially be attributed
to less variance in social anxiety levels in this group. However, it
seems plausible that social anxiety’s inﬂuence on social attention
processes may differ in autistic and neurotypical populations. In
particular, social anxiety may increase arousal and compensatory
avoidance behavior during face processing, especially in indivi-
duals with deﬁcits in interpreting social signals.
Our ﬁndings are in line with a previous study in which social
anxiety increased the avoidance of faces in a simulated public
speaking task in children with ASD.33 It also supplements ﬁndings
from a recent study in which participants with ASD displayed
reduced attention to videos with actors as compared to videos
with objects only under conditions in which the target seemed to
move toward them.52 In contrast, two dot-probe studies detected
no relationship between attentional biases for emotional faces
and anxiety symptoms in autistic subjects.53,54 However, those
studies assessed multiple dimensions of anxiety including
separation anxiety or agoraphobia, and not speciﬁcally social
anxiety. Moreover, social anxiety in ASD may evoke general
avoidance of face cues rather than attentional bias toward speciﬁc
facial expressions; the latter may additionally be confounded by
deﬁcits in emotion recognition in ASD.
The enhancing effect of oxytocin on the allocation of attention
to faces in ASD complements a previous study in which oxytocin
increased attentional bias as well as recognition accuracy for
(positive and neutral) faces but not for nonsocial items (numbers)
during a rapid series visual presentation task in healthy individuals
with heightened autistic traits.16 Together, these ﬁndings support
the assumption that oxytocin may selectively increase the salience
of social information in individuals with low socio-cognitive
abilities.17 As a novel ﬁnding, the improvement in social attention
in ASD by oxytocin was inﬂuenced by individual levels of social
anxiety. Enhancing effects of oxytocin on attention to faces
primarily emerged in autistic individuals with high levels of social
anxiety who displayed an attentional disregard of face stimuli
under placebo conditions. This ﬁnding raises the question
whether oxytocin may enhance social attention in ASD as a
function of social anxiety by decreasing perceptions of social
threat and associated arousal. Such a mechanism would concur
with meta-analytic evidence that oxytocin particularly reduces
stress responses under conditions of strong HPA axis activation,
and in clinical populations with social impairments.55
Social anxiety has been associated with early hypervigilance for
social threat cues (for example, the eye region of faces, aversively
conditioned faces) followed by attentional avoidance of the same
stimuli at a later stage of stimulus processing.56–58 Our ﬁndings
seem to mirror this pattern, as we observed attentional avoidance
of faces speciﬁcally in conjunction with the longer stimulus
duration that allowed for overt attention shifts. This suggests that
oxytocin might counteract the effortful withdrawal of attention
from social cues in anxious individuals with ASD. However, our
data does not clarify whether this effect is speciﬁc to ASD
individuals or is simply driven by anxiety, but was absent in the
control group due to its fewer subjects who scored high on social
anxiety.
The assumption that oxytocin’s anxiolytic and stress-reducing
properties might contribute to its positive effects on social
attention in socially anxious ASD individuals also concurs with
oxytocin’s normalizing effects on attentional biases59 and
amygdala responses36 to emotional faces in social anxiety. In
autistic individuals, oxytocin administration was found to enhance
eye gaze11,60 which is typically impaired in ASD as a function of
reduced attentional orienting and active avoidance of the eye
region.61 Notably, attentional avoidance of the eye region
increases with social anxiety32 and is predictive of emotion
recognition deﬁcits in ASD.32,61 In sum, our ﬁndings deliver
preliminary evidence that oxytocin may help individuals with ASD
to overcome the fear of orienting attention toward a face in the
ﬁrst instance. As this represents a central precondition for ﬁner-
grained face scanning, it may underlie oxytocin’s positive effects
on eye gaze and facial emotion recognition in ASD.
Evidence from imaging studies suggests that altered face
processing in ASD is associated with atypical amygdala
responses62–64 and that oxytocin modulates amygdala responses
during face processing in typically developed persons65 and in
those with ASD.20,22 For instance, oxytocin has recently been
shown to enhance amygdala functioning during face processing
in individuals with ASD.20,22 As this enhancement was associated
with improved emotion recognition performance, it was inter-
preted as an increase in social salience rather than emotional
arousal.20 However, Kleinhans et al.51 note that ﬁndings on altered
amygdala functioning in ASD are inconsistent. They propose that
attentional disregard due to reduced salience of social information
may be associated with the amygdala’s hypoactivation. In
contrast, active avoidance of social stimuli may serve to prevent
emotional overarousal in socially anxious individuals, as reﬂected
in a hyper-reactive amygdala.51 Indeed, social anxiety predicted
amygdala activation to threatening facial expressions in ASD.51
Hence, oxytocin may inﬂuence amygdala reactivity to facial
expression in ASD differentially depending on individual clinical
characteristics along the dimensions of social anxiety and stimulus
aversiveness.
If the oxytocin-induced increase in attention to faces in our
study was indeed mediated by reduced social anxiety, this should
be associated with lower amygdala responses, which would be in
line with weakening oxytocin effects on amygdala responses to
threat-related facial information in social anxiety disorder and
borderline personality disorder.35,36 However, in healthy popula-
tions, oxytocin exerts differential effects on amygdala activation
during attentional orienting and valence processing.66 Future
studies should therefore attempt to disentangle the effects of
oxytocin on amygdala responses during attention- and arousal-
related processes in ASD individuals with low and high levels of
social anxiety. Furthermore, it would be interesting to explore
whether an age-dependent increase in social anxiety in ASD30
may partially explain why the few randomized clinical trials on the
therapeutic potential of oxytocin in ASD observed beneﬁcial
effects of oxytocin mainly in adult populations.19,67–70
It should be noted that, to our knowledge, our study was ﬁrst
and foremost designed to test for oxytocin’s general effects on
social attention in ASD, and not for any moderation or even
mediation of these effects by anxiety measures. Therefore, our
ﬁndings should be considered preliminary and interpreted with
caution. Even though our autistic and neurotypical samples both
showed substantial variance in social anxiety and differed
signiﬁcantly in this measure, a more straight-forward way to
account for the inﬂuence of trait anxiety in future studies might
imply stratiﬁed purposeful sampling techniques or the inclusion of
a socially anxious control group without autism. Moreover,
although we observed no oxytocin effects on state measures of
mood and arousal in our study, it may be worthwhile in future
studies to test explicitly for modulations in stimulus-related
arousal and state anxiety via oxytocin in the context of social
attention.
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Taken together, the present study demonstrates that oxytocin
enhances social attention in ASD and that these effects are
inﬂuenced by social anxiety. Our results reveal that oxytocin may
in particular normalize effortful attentional avoidance of facial
information in ASD individuals with high social anxiety. It may
thereby facilitate more elaborate processing of facial cues in
autistic persons and improve facial emotion recognition as
previously reported. Future studies should investigate whether
oxytocin’s modulatory effects on eye gaze and amygdala
functioning in ASD are attributable to anxiolytic mechanisms, or
are better explained by generally enhanced orienting toward
social cues.
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